Endonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate build up strategy of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | 0.00% | +25.00% | -71.26% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-71.26% | 873K | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development